Document is current
Any future updates will be listed below
-
Authors
Miotto, Marco C. https://orcid.org/0000-0001-8851-4863
Reiken, Steven
Wronska, Anetta https://orcid.org/0000-0003-2288-2596
Yuan, Qi
Dridi, Haikel https://orcid.org/0000-0001-9533-7367
Liu, Yang
Weninger, Gunnar https://orcid.org/0009-0009-1836-4316
Tchagou, Carl
Marks, Andrew R. https://orcid.org/0000-0002-4316-5775
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5R01HL145473, 5R01HL140934, 1P01HL164319)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
- License Information
-
More Information
Article History
Received: 19 December 2023
Accepted: 12 August 2024
First Online: 15 September 2024
Competing interests
: A.R.M. is a member of the scientific advisory board and board of directors and an equity owner in ARMGO Pharma Inc. a biotech company developing RyR targeted therapeutics. Columbia University also owns equity in ARMGO Inc. A.R.M. has patent applications or pending or awarded patents, including U.S. 2014/0378437 and U.S. 7,718,644. The remaining authors declare no competing interests.
